- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
December 18, 2018
In this episode of Px Pulse, we consider how future HIV prevention trials will need to be designed as HIV prevention evolves... and how to strengthen community engagement along with it. At the heart of the matter is that clinical trials for HIV prevention are set to get bigger and more complex, in response to advances in HIV prevention, such as PrEP. Px Pulse started talking about this back in October 2017 with a look at the double-dummy double-blind trial designs of injectable PrEP.
The field heard some of the latest thinking on future trial design at the HIV Research for Prevention (R4P) conference in October. Px Pulse picks up the conversation with a special focus on the implications for the all-important work of community engagement around trial design.
Three advocates join us to frame the issues and trade ideas:
- Morenike Giwa-Onaiwu who heads up the Houston HIV Cross-Network Community Advisory Board
- Stacey Hannah is AVAC’s Director of Research Engagment
- Jeremiah Johnson is the HIV Project Director for the Treatment Action Group
Listen to the full podcast (15:42)
Highlights
- Current challenges facing community engagement (7:58)
- Why trial design is changing and what it means for advocates (8:16)
Additional Resources
- Testing Long-Acting PrEP, Easier Said Than Done (Px Pulse, October 2017)
- An Advocate's Guide to Research Terms in the Post-Placebo Era
- Community Involvement in HIV Vaccine Research: Making it work
- DISCOVER Trial Factsheet
- The Years Ahead in Biomedical HIV Prevention Research
- The Future of ARV-Based Prevention and More
- HIV-Specific Neutralizing Antibodies - Targets and research status
- Vaccine Efficacy Trials Pipeline
- Beyond the Trial: What impact does engagement and participatory practice have on HIV research outcomes?
GPP Specific Materials
- "Science, Theory and Practice of Engaged Research: Good Participatory Practice and beyond." A 2018 special supplement of the Journal of the International AIDS Society
- Good Participatory Practice Tools for conducting trainings or implementing a GPP process, or for monitoring and evaluation
- GPP Guidelines